

**AMENDMENTS TO THE SPECIFICATION:**

Page 1, line 1, delete the first paragraph in its entirety and replace it with the following new paragraph:

This application is a continuation of U.S. Application No. 09/539,774, filed March 31, 2000, now USP 6,350,615, which is a continuation of U.S. Application No. 09/210,474, filed December 14, 1998, now USP 6,072,034, which is a continuation of U.S. Application No. 08/755,559, filed November 22, 1996, now USP 5,912,142. The entire contents of these applications are incorporated herein by reference.

Please amend the paragraph beginning at page 6, line 13, as follows:

Figure 1. Predicted amino acid sequence of the human K12 gene product deduced from the human K12 cDNA sequence (SEQ ID NO:1). The underlined region is the proposed membrane spanning domain.

Please amend the paragraph beginning at page 6, line 17, as follows:

Figure 2. Human K12 cDNA sequence ) (SEQ ID NO:2). K12 promoter (1-195) and cDNA (196-2180).

Please amend the paragraph beginning at page 15, line 13, as follows:

The compound is preferably a binding protein, eg an antibody, polyclonal or monoclonal, or antigen binding fragment thereof. Monoclonal antibody 7C3 is preferred (a hybridoma producing antibody 7C3 was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20552 (new address: 10801 University Boulevard, Manassas, VA 20110-2209), on November 19, 1996, under the terms of the Budapest Treaty under Accession No. ATCC HB-12238).